ClinicalTrials.gg
RecruitingNCT07105176Updated Oct 14, 2026

HS-IT101 Injection for Advanced NSCLC(FASTIL-Lung01)

A Phase 1 interventional study of Cyclophosphamide and Fludarabine in Advanced Non-Small Cell Lung Cancer, sponsored by Hangzhou Huasai Biomedicine Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Hangzhou Huasai Biomedicine Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Oct 14, 2026Now RecruitingSite recruiting status changed+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing cyclophosphamide in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 5 under way, none of them phase 3. Cyclophosphamide · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
12th of 19
12 · median 16
Started
2026
the only one that year
Phase 1
9 of 19
1 open now
Registered
19th of 19
by date
Lead sponsor
1 of 19
Hangzhou Huasai Biomedicine Co., Ltd.

Among the 19 studies testing cyclophosphamide in Carcinoma, Non-Small-Cell Lung, this one is the 12th largest by planned enrollment, is the only one that started in 2026, is one of 9 in phase 1, and was the 19th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 19 studies testing cyclophosphamide in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing cyclophosphamide in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

An Open-Label, Single-Arm Phase Ib Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of HS-IT101 Injection in Subjects with Advanced NSCLC.

Read the detailed description

A Single-Arm, Open-Label, Interventional Study Evaluating Adoptive Cell Therapy (ACT) with Autologous Tumor-Infiltrating Lymphocytes (HS-IT101) Following Lymphodepleting Conditioning with Fludarabine and Cyclophosphamide, Followed by IL-2 in Patients with Advanced NSCLC.

03

Conditions studied

  • Advanced Non-Small Cell Lung Cancer
04

Who can participate

The criteria were revised on the registry on Oct 14, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18 to 75 years old;
  2. Patients with advanced, recurrent, or non-small cell lung cancer (NSCLC) who have been confirmed by cytology or histology and have failed at least one line of standard therapy. Patients with non-squamous NSCLC who are negative for EGFR/ALK/ROS1 driver mutations.
  3. There must be at least one tumor lesion that has not undergone radiation therapy or other local treatments within the past 28 days, which will be used to prepare autologous tumor-infiltrating lymphocytes, and it must meet the tissue sampling requirements.
  4. After sampling, there must be at least one that meets the 1.1 criteria definition, and this lesion has not undergone radiotherapy or other local treatments;
  5. score ≤ 1;
  6. The expected survival time is ≥ 3 months;
  7. During the screening period, the assessments showed adequate organ and bone marrow function,
  8. Echocardiography shows (LVEF) ≥50%; no arrhythmias requiring treatment; corrected by the Fridericia method (QTcF) ≤470 ms; baseline blood oxygen saturation >91% in ambient air conditions;
  9. Prior to tumor sampling, adverse reactions induced by previous treatments have recovered to Grade 1 (5.0) or below according to the (CTCAE) version 5.0;
  10. From the signing of the form to one year after TIL cell infusion, agree to adopt effective non-pharmacological measures;
  11. Those who fully understand this trial and voluntarily sign the informed consent form, and are able to comply with the visits and related procedures stipulated in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have previously experienced severe allergic reactions to drugs used during the research process;
  2. Presence of any uncontrolled clinical conditions, including but not limited to: poorly controlled hypertension; congestive heart failure;
  3. Within the past 6 months, the following conditions have occurred: deep vein thrombosis or pulmonary embolism; myocardial infarction; severe or unstable arrhythmia or angina; percutaneous coronary intervention, acute coronary syndrome, or coronary artery bypass grafting; cerebrovascular accident, , or cerebral embolism;
  4. diseases that are active and require systemic treatment during the study period;
  5. Organ transplantation or a history of hematopoietic stem cell transplantation;
  6. Within 4 weeks prior to tumor tissue sampling, the subject has used any drugs, such as medications, or the investigator determines that there are comorbid conditions requiring the use of immunosuppressive drugs during the trial. However, physiological doses of glucocorticoids are permitted, and intranasal or local use of steroid medications is allowed;
  7. Individuals who have received systemic anti-tumor treatment within the 4 weeks prior to pre-treatment or those planning to participate in other interventional clinical trials during the study period;
  8. Presence of acute or chronic infections, active infections requiring systemic treatment, or active tuberculosis infection;
  9. Individuals who have undergone major organ surgery or suffered significant trauma within the past 4 weeks, or who require elective surgery during the trial period;
  10. Patients with pre-selection surgical complications or delayed healing, and those judged by the researcher to be at increased risk for lymph node clearance pretreatment, adoptive TIL therapy, and IL-2 therapy;
  11. Within the 5 years prior to screening, diagnosed with concurrent other primary malignant tumors, excluding completely resected cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, and/or in situ carcinoma that has undergone radical excision;
  12. Suffering from severe respiratory diseases;
  13. Patients with gastrointestinal bleeding requiring surgical treatment, or those with localized intestinal ischemia or perforation;
  14. Patients with known ; patients with other central nervous system that are not effectively controlled by treatment or have not been treated;
  15. Has previously received similar cell therapy products;
  16. Pregnant or lactating women;
  17. Individuals with known mental illnesses, alcoholism, drug or substance abuse, or those deemed unsuitable by other researchers to participate in this trial.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    HS-IT101 monotherapy

    TIL Injection administered by intravenous infusion over 30-60 minutes.

    Drug: Cyclophosphamide · Drug: Fludarabine · Drug: IL-2 (interleukin 2)

Interventions

  • Cyclophosphamide administered via intravenous infusion once daily for 3 consecutive days.

  • Fludarabine is administered once daily via intravenous infusion for 3 consecutive days.

  • IL-2 is administered subcutaneously or intravenously once daily. The dose may be adjusted based on the subject's tolerance, including modifications to the dose, dosing frequency, or complete discontinuation of treatment, Up to three administrations.

06

What researchers measure

Primary outcomes

  1. Adverse Events (AE)

    To characterize the safety profile of HS-IT101 in patients with advanced solid tumor as assessed by incidence of adverse events

    Time frame: 12 months

  2. Serious Adverse Events (SAE)

    To characterize the safety profile of HS-IT101 in patients with advanced solid tumor as assessed by incidence of serious adverse events

    Time frame: 12 months

  3. Objective Response Rate (ORR)

    To evaluate the efficacy of HS-IT101 in patients with advanced solid tumor, based on the objective response rate (ORR) as assessed by the Independent Review Committee (IRC) per RECIST v1.1

    Time frame: Up to 36 months

  4. Time-to-response (TTR)

    To evaluate the efficacy of HS-IT101 in patients with advanced solid tumor by assessing the time-to-response (TTR) as assessed by the Investigator per RECIST v1.1

    Time frame: Up to 36 months

  5. Duration of Response (DOR)

    To evaluate the efficacy of HS-IT101 in patients with advanced solid tumor by assessing the duration of response (DOR) as assessed by the Investigator per RECIST v1.1

    Time frame: Up to 36 months

  6. Disease Control Rate (DCR)

    To evaluate the efficacy of HS-IT101 in patients with advanced solid tumor, based on the disease control rate (DCR) as assessed by the Independent Review Committee (IRC) per RECIST v1.1

    Time frame: Up to 36 months

Secondary outcomes

  1. Progression-Free-Survival (PFS)

    To evaluate progression-free-survival (PFS) in patients with advanced solid tumor

    Time frame: Up to 36 months

  2. Overall Survival (OS)

    To evaluate overall survival (OS) in patients with advanced solid tumor

    Time frame: Up to 36 months

  3. Pharmacokinetic (PK) detection parameters for HS-IT101

    peripheral blood lymphocyte subsets .

    Time frame: Up to 6 months

  4. Pharmacokinetic (PK) detection parameters for HS-IT101

    T-cell receptor (TCR) clonality

    Time frame: Up to 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Aug 2027, 12 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 12 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: start Aug 2025 → Aug 2026, primary completion Aug 2026 → Aug 2027 and completion Aug 2027 → Aug 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2025
First posted
Aug 5, 2025
StartActual
Aug 30, 2026was Aug 2025
Primary completionEst.
Aug 30, 2027was Aug 2026
CompletionEst.
Aug 30, 2028was Aug 2027
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 14, 2026
Sites
Guangdong Provincial People's Hospital is now Recruiting
Oct 14, 2026
Start date
Aug 30, 2025→Aug 30, 2026 (actual)
Oct 14, 2026
Primary completion
Aug 30, 2026→Aug 30, 2027
Oct 14, 2026
Study completion
Aug 30, 2027→Aug 30, 2028
Oct 14, 2026
Eligibility
Maximum age 70 Years→75 Years; Criteria largely rewritten (70 changes)
What changed in the criteria
Inclusion criteria
  • RemovedAge: 18-70 years (inclusive).
  • RemovedDiagnosis:
  • RemovedHistologically/cytologically confirmed advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) .
  • RemovedTumor Sampling:
  • Removed≥1 lesion untreated with radiotherapy/local therapy within 28 days for TIL preparation (tissue weight ≥0.050 g).
  • RemovedTarget Lesion:
  • Removed≥1 measurable lesion per RECIST v1.1, untreated with radiotherapy/local therapy (unless treatment occurred >28 days before sampling with documented progression).
  • RemovedPerformance Status: ECOG score ≤1. Survival: Life expectancy ≥3 months.
  • RemovedOrgan Function:
  • RemovedHematology: ANC ≥1.5×10⁹/L, PLT ≥90×10⁹/L, HGB ≥90 g/L (no transfusion/erythropoietin within 14 days).
  • RemovedLiver: ALT/AST ≤2.5×ULN (≤5×ULN if liver metastases); TBil ≤1.5×ULN (≤3×ULN for Gilbert syndrome).
  • RemovedKidney: Serum Cr ≤1.5×ULN or Ccr ≥60 mL/min (Cockcroft-Gault formula). Coagulation: APTT ≤1.5×ULN; INR/PT ≤1.5×ULN.
  • RemovedCardiac Function:
  • RemovedLVEF ≥50% by echocardiography; QTcF ≤470 ms (Fridericia formula: QTcF = QT/RR⁰·³³).
  • RemovedBaseline SpO₂ >91% (room air). Note: If QTcF is abnormal initially, repeat twice at ≥5-minute intervals and use mean value for eligibility.
  • RemovedToxicity Recovery: All treatment-related adverse events resolved to CTCAE v5.0 ≤Grade 1 (except alopecia/non-risk toxicities per investigator) before tumor sampling.
  • RemovedContraception: Effective non-pharmacological contraception from informed consent until 1 year post-TIL infusion.
  • RemovedCompliance: Capable of understanding the trial, voluntarily signing informed consent, and adhering to protocol visits/procedures.
  • AddedAge: 18 to 75 years old;
  • AddedPatients with advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) who have been confirmed by cytology or histology and have failed at least one line of standard first-line therapy. Patients with non-squamous NSCLC who are negative for EGFR/ALK/ROS1 driver mutations.
  • AddedThere must be at least one tumor lesion that has not undergone radiation therapy or other local treatments within the past 28 days, which will be used to prepare autologous tumor-infiltrating lymphocytes, and it must meet the tissue sampling requirements.
  • AddedAfter sampling, there must be at least one measurable lesion that meets the RECIST 1.1 criteria definition, and this lesion has not undergone radiotherapy or other local treatments;
  • AddedECOG score ≤ 1;
  • AddedThe expected survival time is ≥ 3 months;
  • AddedDuring the screening period, the assessments showed adequate organ and bone marrow function,
  • AddedEchocardiography shows left ventricular ejection fraction (LVEF) ≥50%; no arrhythmias requiring treatment; QT interval corrected by the Fridericia method (QTcF) ≤470 ms; baseline blood oxygen saturation >91% in ambient air conditions;
  • AddedPrior to tumor sampling, adverse reactions induced by previous treatments have recovered to Grade 1 (5.0) or below according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0;
  • AddedFrom the signing of the informed consent form to one year after TIL cell infusion, agree to adopt effective non-pharmacological contraception measures;
  • AddedThose who fully understand this trial and voluntarily sign the informed consent form, and are able to comply with the visits and related procedures stipulated in the protocol.
Exclusion criteria
  • RemovedSevere Hypersensitivity: History of severe hypersensitivity to drugs used in the study (including but not limited to cyclophosphamide, fludarabine, IL-2, gentamicin, amphotericin B, or components of TIL infusion).
  • RemovedUncontrolled Comorbidities:
  • RemovedPoorly controlled hypertension (resting SBP ≥160 mmHg or DBP ≥100 mmHg despite medication).
  • RemovedCongestive heart failure (NYHA Class III/IV).
  • RemovedCardiovascular Events (within 6 months):
  • RemovedDeep vein thrombosis, pulmonary embolism, myocardial infarction, severe/unstable arrhythmia, angina, PCI, ACS, CABG, stroke, TIA, or cerebral embolism.
  • RemovedActive Autoimmune Disease:
  • RemovedRequires systemic therapy during the study period (Exceptions: Eczema, vitiligo, psoriasis, alopecia, or Graves' disease stable without systemic therapy for 2 years; hypothyroidism on hormone replacement; type 1 diabetes on insulin).
  • AddedPatients who have previously experienced severe allergic reactions to drugs used during the research process;
  • AddedPresence of any uncontrolled clinical conditions, including but not limited to: poorly controlled hypertension; congestive heart failure;
  • AddedWithin the past 6 months, the following conditions have occurred: deep vein thrombosis or pulmonary embolism; myocardial infarction; severe or unstable arrhythmia or angina; percutaneous coronary intervention, acute coronary syndrome, or coronary artery bypass grafting; cerebrovascular accident, transient ischemic attack, or cerebral embolism;

…and 30 more changes, on the record history on ClinicalTrials.gov ↗

Oct 14, 2026
Interventions
Removed Drug: HS-IT101 monotherapy
Oct 14, 2026
Title
HS-IT101 Injection for Advanced NSCLC(FASTIL-Lung01)
Oct 14, 2026
Sponsor
Qingdao Sino-Cell Biomedicine Co., Ltd.→Hangzhou Huasai Biomedicine Co., Ltd.
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Not yet recruiting→Recruiting
    Guangdong Provincial People's Hospital is now Recruiting
    Start date Aug 30, 2025→Aug 30, 2026 (now actual)
    Primary completion Aug 30, 2026→Aug 30, 2027
    Study completion Aug 30, 2027→Aug 30, 2028
    Eligibility Maximum age 70 Years→75 Years; Criteria largely rewritten (70 changes)
    What changed in the criteria
    Inclusion criteria
    • RemovedAge: 18-70 years (inclusive).
    • RemovedDiagnosis:
    • RemovedHistologically/cytologically confirmed advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) .
    • RemovedTumor Sampling:
    • Removed≥1 lesion untreated with radiotherapy/local therapy within 28 days for TIL preparation (tissue weight ≥0.050 g).
    • RemovedTarget Lesion:
    • Removed≥1 measurable lesion per RECIST v1.1, untreated with radiotherapy/local therapy (unless treatment occurred >28 days before sampling with documented progression).
    • RemovedPerformance Status: ECOG score ≤1. Survival: Life expectancy ≥3 months.
    • RemovedOrgan Function:
    • RemovedHematology: ANC ≥1.5×10⁹/L, PLT ≥90×10⁹/L, HGB ≥90 g/L (no transfusion/erythropoietin within 14 days).
    • RemovedLiver: ALT/AST ≤2.5×ULN (≤5×ULN if liver metastases); TBil ≤1.5×ULN (≤3×ULN for Gilbert syndrome).
    • RemovedKidney: Serum Cr ≤1.5×ULN or Ccr ≥60 mL/min (Cockcroft-Gault formula). Coagulation: APTT ≤1.5×ULN; INR/PT ≤1.5×ULN.
    • RemovedCardiac Function:
    • RemovedLVEF ≥50% by echocardiography; QTcF ≤470 ms (Fridericia formula: QTcF = QT/RR⁰·³³).
    • RemovedBaseline SpO₂ >91% (room air). Note: If QTcF is abnormal initially, repeat twice at ≥5-minute intervals and use mean value for eligibility.
    • RemovedToxicity Recovery: All treatment-related adverse events resolved to CTCAE v5.0 ≤Grade 1 (except alopecia/non-risk toxicities per investigator) before tumor sampling.
    • RemovedContraception: Effective non-pharmacological contraception from informed consent until 1 year post-TIL infusion.
    • RemovedCompliance: Capable of understanding the trial, voluntarily signing informed consent, and adhering to protocol visits/procedures.
    • AddedAge: 18 to 75 years old;
    • AddedPatients with advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) who have been confirmed by cytology or histology and have failed at least one line of standard first-line therapy. Patients with non-squamous NSCLC who are negative for EGFR/ALK/ROS1 driver mutations.
    • AddedThere must be at least one tumor lesion that has not undergone radiation therapy or other local treatments within the past 28 days, which will be used to prepare autologous tumor-infiltrating lymphocytes, and it must meet the tissue sampling requirements.
    • AddedAfter sampling, there must be at least one measurable lesion that meets the RECIST 1.1 criteria definition, and this lesion has not undergone radiotherapy or other local treatments;
    • AddedECOG score ≤ 1;
    • AddedThe expected survival time is ≥ 3 months;
    • AddedDuring the screening period, the assessments showed adequate organ and bone marrow function,
    • AddedEchocardiography shows left ventricular ejection fraction (LVEF) ≥50%; no arrhythmias requiring treatment; QT interval corrected by the Fridericia method (QTcF) ≤470 ms; baseline blood oxygen saturation >91% in ambient air conditions;
    • AddedPrior to tumor sampling, adverse reactions induced by previous treatments have recovered to Grade 1 (5.0) or below according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0;
    • AddedFrom the signing of the informed consent form to one year after TIL cell infusion, agree to adopt effective non-pharmacological contraception measures;
    • AddedThose who fully understand this trial and voluntarily sign the informed consent form, and are able to comply with the visits and related procedures stipulated in the protocol.
    Exclusion criteria
    • RemovedSevere Hypersensitivity: History of severe hypersensitivity to drugs used in the study (including but not limited to cyclophosphamide, fludarabine, IL-2, gentamicin, amphotericin B, or components of TIL infusion).
    • RemovedUncontrolled Comorbidities:
    • RemovedPoorly controlled hypertension (resting SBP ≥160 mmHg or DBP ≥100 mmHg despite medication).
    • RemovedCongestive heart failure (NYHA Class III/IV).
    • RemovedCardiovascular Events (within 6 months):
    • RemovedDeep vein thrombosis, pulmonary embolism, myocardial infarction, severe/unstable arrhythmia, angina, PCI, ACS, CABG, stroke, TIA, or cerebral embolism.
    • RemovedActive Autoimmune Disease:
    • RemovedRequires systemic therapy during the study period (Exceptions: Eczema, vitiligo, psoriasis, alopecia, or Graves' disease stable without systemic therapy for 2 years; hypothyroidism on hormone replacement; type 1 diabetes on insulin).
    • AddedPatients who have previously experienced severe allergic reactions to drugs used during the research process;
    • AddedPresence of any uncontrolled clinical conditions, including but not limited to: poorly controlled hypertension; congestive heart failure;
    • AddedWithin the past 6 months, the following conditions have occurred: deep vein thrombosis or pulmonary embolism; myocardial infarction; severe or unstable arrhythmia or angina; percutaneous coronary intervention, acute coronary syndrome, or coronary artery bypass grafting; cerebrovascular accident, transient ischemic attack, or cerebral embolism;

    …and 30 more changes, on the record history on ClinicalTrials.gov ↗

    Interventions Removed Drug: HS-IT101 monotherapy
    Sponsor Qingdao Sino-Cell Biomedicine Co., Ltd.→Hangzhou Huasai Biomedicine Co., Ltd.
    Title HS-IT101 Injection for Advanced NSCLC(FASTIL-Lung01)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07105176
Lead sponsor
Hangzhou Huasai Biomedicine Co., Ltd.
Responsible party
Sponsor
First posted
Aug 5, 2025
Start date
Aug 30, 2026
Primary completion
Aug 30, 2027 (estimated)
Completion
Aug 30, 2028 (estimated)
Last update
Oct 14, 2026

Study contacts

WenNa.Liu
Contact
med@sino-cellbiomed.com
(86)400-6786-208

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclophosphamide · Fludarabine · Interleukin-2

Start the discussion